The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies

Developmental Medicine and Child Neurology

Volumn 55, Issue 7, 2013, Pages 654-660

  Santos, Kleber ^a   Palmini, Andre ^a   Radziuk, Ana L ^a   Rotert, Rosana ^a   Bastos, Fernanda ^a   Booij, Linda ^b,c,d   Fernandes, Brisa S ^e  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD BEHAVIOR CHECKLIST; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOCAL EPILEPSY; HAGUE SEIZURE SEVERITY SCALE; HUMAN; LOW DRUG DOSE; MALE; NERVOUS SYSTEM PARAMETERS; OUTCOME ASSESSMENT; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCHOOL CHILD; SEIZURE; SIDE EFFECTS RATING SCALE; SWANSON NOLAN PELHAM QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; CLASSIFICATION; CLINICAL TRIAL; COMORBIDITY; EPILEPSY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COMORBIDITY; EPILEPSY; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PILOT PROJECTS; SEIZURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84881496379     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.12121     Document Type: Article

References (26)

1. Sillanpaa M. Children with epilepsy as adults: outcome after 30 years of follow-up. Acta Paediatr Suppl 1990; 368: 1-78.
2. Davies S, Heyman I, Goodman R. A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol 2003; 45: 292-5.
3. Ott D, Siddarth P, Gurbani S, et al. Behavioral disorders in pediatric epilepsy: unmet psychiatric need. Epilepsia 2003; 44: 591-7.
4. Camfield CS, Camfield PR. Long-term social outcomes for children with epilepsy. Epilepsia 2007; 48(Suppl. 9): 3-5.
5. Seidenberg M, Pulsipher DT, Hermann B. Association of epilepsy and comorbid conditions. Future Neurol 2009; 4: 663-8.
6. Sherman EM, Slick DJ, Connolly MB, Eyrl KL. ADHD, neurological correlates and health-related quality of life in severe pediatric epilepsy. Epilepsia 2007; 48: 1083-91.
7. Reilly CJ. Attention deficit hyperactivity disorder (ADHD) in childhood epilepsy. Res Dev Disabil 2011; 32: 883-93.
8. Chamberlain RW. Convulsions and ritalin? Pediatrics 1974; 54: 658-9.
9. Gonzalez-Heydrich J, Whitney J, Waber D, et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav 2010; 18: 229-37.
10. Feldman H, Crumrine P, Handen BL, Alvin R, Teodori J. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989; 143: 1081-6.
11. Gross-Tsur V, Manor O, van der Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997; 130: 670-4.
12. Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18: 109-12.
13. Koneski JA, Casella EB, Agertt F, Ferreira MG. Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review. Epilepsy Behav 2011; 21: 228-32.
14. American Psychiatric Association. Task Force on D-I. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association, 1994.
15. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40: 168-79.
16. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-8.
17. Achenbach TM, Rescorla LA. Manual for the ASEBA School-Age Forms & Profiles. Burlington, VT: Research Center for Children, Youth, & Families, University of Vermont, 2001.
18. Wechsler D. WISC-III: Escala de inteligência de Weschler para crianças. Adaptação e padronização brasileira. São Paulo: Casa do Psicólogo, 2002.
19. Carpay HA, Arts WF, Vermeulen J, et al. Parent-completed scales for measuring seizure severity and severity of side-effects of antiepileptic drugs in childhood epilepsy: development and psychometric analysis. Epilepsy Res 1996; 24: 173-81.
20. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86: 184-92.
21. van den Ban EF, Souverein PC, Meijer WM, et al. Accident proneness among youth treated with ADHD medication. Pharmacoepidemiol Drug Saf 2011; 20: S133-4.
22. Handen BL, Breaux AM, Gosling A, Ploof DL, Feldman H. Efficacy of methylphenidate among mentally-retarded children with attention-deficit hyperactivity disorder. Pediatrics 1990; 86: 922-30.
23. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56: 1073-86.
24. Gara L, Roberts W. Adverse response to methylphenidate in combination with valproic acid. J Child Adolesc Psychopharmacol 2000; 10: 39-43.
25. Dinner DS. Effect of sleep on epilepsy. J Clin Neurophysiol 2002; 19: 504-13.
26. McNaughton FL, Lloyd-Smith D. Drugs for major epileptic seizures. Can Med Assoc J 1965; 93: 607-8.